1-4 of 4
Howard S. Hochster
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

E. Gabriela Chiorean, Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia Jalikis, Michael J. Pishvaian, Jordan Berlin, Marcus S. Noel, Jennifer M. Suga, Ignacio Garrido-Laguna, Dana Backlund Cardin, Marc R. Radke, Mai Duong, Shay Bellasea, Andrew M. Lowy, Howard S. Hochster
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6314–6322.
https://doi.org/10.1158/1078-0432.CCR-21-1789
Published: 01 December 2021
View article titled, Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
Open the PDF for Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513 in another window
Includes: Supplementary data
Journal Articles

Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Zev A. Wainberg, Howard S. Hochster, Edward J. Kim, Ben George, Aparna Kaylan, E. Gabriela Chiorean, David M. Waterhouse, Martin Guiterrez, Aparna Parikh, Rishi Jain, Daniel Ricardo Carrizosa, Hatem H. Soliman, Thomas Lila, David J. Reiss, Daniel W. Pierce, Rafia Bhore, Sibabrata Banerjee, Larry Lyons, Chrystal U. Louis, Teng Jin Ong, Peter J. O'Dwyer
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (18): 4814–4822.
https://doi.org/10.1158/1078-0432.CCR-20-0099
Published: 15 September 2020
View article titled, Open-label, Phase I Study of Nivolumab Combined with <em>nab</em>-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
Open the PDF for Open-label, Phase I Study of Nivolumab Combined with <em>nab</em>-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors

Anna M. Varghese, Dana B. Cardin, Jonathan Hersch, Al B. Benson, Howard S. Hochster, Lukas Makris, Kensuke Hamada, Jordan D. Berlin, Leonard B. Saltz
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (7): 1555–1562.
https://doi.org/10.1158/1078-0432.CCR-19-2743
Published: 01 April 2020
View article titled, Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors
Open the PDF for Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors in another window
Includes: Supplementary data
Journal Articles

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)

Megan Li, Flora Mulkey, Chen Jiang, Bert H. O’Neil, Bryan P. Schneider, Fei Shen, Paula N. Friedman, Yukihide Momozawa, Michiaki Kubo, Donna Niedzwiecki, Howard S. Hochster, Heinz-Josef Lenz, James N. Atkins, Hope S. Rugo, Susan Halabi, William Kevin Kelly, Howard L. McLeod, Federico Innocenti, Mark J. Ratain, Alan P. Venook, Kouros Owzar, Deanna L. Kroetz
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (19): 4734–4744.
https://doi.org/10.1158/1078-0432.CCR-17-1523
Published: 01 October 2018
View article titled, Identification of a Genomic Region between <em>SLC29A1</em> and <em>HSP90AB1</em> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)
Open the PDF for Identification of a Genomic Region between <em>SLC29A1</em> and <em>HSP90AB1</em> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance) in another window
Includes: Supplementary data